BJL
AXSM icon

Brighton Jones LLC’s Axsome Therapeutics AXSM Stock Holding History

Brighton Jones LLC’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+858
New +$186K ﹤0.01% 1233

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Brighton Jones LLC's AXSM Position: Q2 2026 in Review

Brighton Jones LLC opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 858 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #1233 among its holdings.

248 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Brighton Jones LLC held 858 shares of Axsome Therapeutics worth $210K as of Q2 2026.
  • Axsome Therapeutics was a new Brighton Jones LLC position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1233 holding.
  • 248 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.